Animal models of prostate cancer

Source Book of Models for Biomedical Research

Volumn , Issue , 2008, Pages 639-649

  Alagbala, Adebusola A ^a   Foster, Barbara A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Bigenic mice; Canine models; Genetically engineered mouse models; Human prostate cancer xenograft models; Prostate cancer; Prostate gland; Rodent models; SV40 T antigens; Transgenic mice

Indexed keywords

EID: 79960771200     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-285-4_66     Document Type: Chapter

References (148)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
2. Khan MA, Partin AW. Expectant management: An option for localized prostate cancer. Prostate Cancer Prostatic Dis 2005;8:311-315.
3. American Cancer Society (ACS) website. http://www.cancer.org.
4. Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367-3371.
5. Steinberg GD, Carter BS, Beaty TH, Childs B, Walsh PC. Family history and the risk of prostate cancer. Prostate 1990;17:337-347.
6. Bostwick DG, Ramnani D, Qian J. Prostatic intraepithelial neoplasia: Animal models 2000. Prostate 2000;43:286-294.
7. Lucia MS, Bostwick DG, Bosland M, et al. Workgroup I: Rodent models of prostate cancer. Prostate 1998;36:49-55.
8. Waters DJ, Hayden DW, Bell FW, Klausner JS, Qian J, Bostwick DG. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 1997;30:92-97.
9. Waters DJ, Sakr WA, Hayden DW, et al. Workgroup 4: Spontaneous prostate carcinoma in dogs and nonhuman primates. Prostate 1998;36:64-67.
10. Aquilina JW, McKinney L, Pacelli A, et al. High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer. Prostate 1998;36:189-193.
11. Sugimura Y, Cunha GR, Donjacour AA. Morphogenesis of ductal networks in the mouse prostate. Biol Reprod 1986;34:961-971.
12. Neumann F, Elger W, Steinbeck H. Antiandrogens and reproductive development. Philos Trans R Soc Lond B Biol Sci 1970;259:179-184.
13. Elger W, Graf KJ, Steinbeck H, Neumann F. Hormonal control of sexual development. Adv Biosci 1974;13:41-69.
14. Neumann F, Graf KJ, Elger W. Hormone-induced disturbances in sexual differentiation. Adv Biosci 1974;13:71-101.
15. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocrine Rev 1987;8:338-362.
16. Isaacs JT. Prostatic structure and function in relation to the etiology of prostatic cancer. Prostate 1983;4:351-366.
17. Hoehn W, Schroeder FH, Reimann JF, Joebsis AC, Hermanek P. Human prostatic adenocarcinoma: Some characteristics of a serially transplantable line in nude mice (PC 82). Prostate 1980;1:95-104.
18. van Weerden WM, de Ridder CM, Verdaasdonk CL, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996;149:1055-1062.
19. van Weerden WM, Romijn JC. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000;43:263-271.
20. Navone NM, Logothetis CJ, von Eschenbach AC, Troncoso P. Model systems of prostate cancer: Uses and limitations. Cancer Metastasis Rev 1998;17:361-371.
21. Wainstein MA, He F, Robinson D, et al. CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54:6049-6052.
22. Nagabhushan M, Miller CM, Pretlow TP, et al. CWR22: The fi rst human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56:3042-3046.
23. Ellis WJ, Vessella RL, Buhler KR, et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996;2:1039-1048.
24. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodefi-cient SCID mice. Nat Med 1997;3:402-408.
25. Wang Y, Xue H, Cutz JC, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005;85:1392-1404.
26. Waters DJ, Patronek GJ, Bostwick DG, Glickman LT. Comparing the age at prostate cancer diagnosis in humans and dogs. J Natl Cancer Inst 1996;88:1686-1687.
27. McNeal JE. Origin and development of carcinoma in the prostate. Cancer 1969;23:24-34.
28. McNeal JE. The prostate gland: Morphology and pathobiology. Monogr Urol 1983;4:3-37.
29. McNeal JE. Normal histology of the prostate. Am J Surg Pathol 1988;12:619-633.
30. Price D. Comparative aspects of development and structure in the prostate. Natl Cancer Inst Monogr 1963;12:1-27.
31. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-2434.
32. Shappell SB, Thomas GV, Roberts RL, et al. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res 2004;64:2270-2305.
33. Lubaroff DM, Canfield L, Reynolds CW. The Dunning tumors. Prog Clin Biol Res 1980;37:243-263.
34. Pollard M, Luckert PH. Transplantable metastasizing prostate adenocarcinomas in rats. J Natl Cancer Inst 1975;54:643-649.
35. Pollard M, Luckert PH. Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-Nmethylurea and testosterone. J Natl Cancer Inst 1986;77:583-587.
36. Dunning WF. Prostate cancer in the rat. Natl Cancer Inst Monogr 1963;12:351-369.
37. Lubaroff DM, Canfield L, Rasmussen GT, Reynolds CW. An animal model for the study of prostate carcinoma. Natl Cancer Inst Monogr 1978;49:275-281.
38. Isaacs JT, Weissman RM, Coffey DS, Scott WW. Concepts in prostatic cancer biology: Dunning R-3327 H, HI, and AT tumors. Prog Clin Biol Res 1980;37:311-323.
39. Isaacs JT, Yu GW, Coffey DS. The characterization of a newly identifi ed, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: The MAT LyLu tumor. Invest Urol 1981;19:20-23.
40. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
41. Isaacs JT. The R-3327 system of rat prostatic cancers. Urol Oncol Semin Orig Invest 1996;2:115-116.
42. Geldof AA, Rao BR. Prostatic tumor (R3327) skeletal metastasis. Prostate 1990;16:279-290.
43. Goebel HW, Rausch U, Steinhoff M, et al. Arguments against the prostatic origin of the R-3327 Dunning H tumor. Virchows Arch B Cell Pathol Incl Mol Pathol 1992;62:9-18.
44. Pollard M, Luckert PH. Autochthonous prostate adenocarcinomas in Lobund-Wistar rats: A model system. Prostate 1987;11:219-227.
45. Pollard M, Luckert PH, Schmidt MA. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate 1982;3: 563-568.
46. Pollard M, Suckow MA. Hormone-refractory prostate cancer in the Lobund-Wistar rat. Exp Biol Med 2005;230:520-526.
47. Sigmund C. Major approaches for generating and analyzing transgenic mice. An overview. Hypertension 1993;22:599-607.
48. Asamoto M, Hokaiwado N, Cho Y-M, et al. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001;61:4693-4700.
49. al-Shawi R, Kinnaird J, Burke J, Bishop JO. Expression of a foreign gene in a line of transgenic mice is modulated by a chromosomal position effect. Mol Cell Biol 1990;10:1192-1198.
50. Greenberg NM, DeMayo FJ, Sheppard PC, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol Endocrinol 1994;8:230-239.
51. Greenberg NM, DeMayo F, Finegold MJ, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995;92:3439-3443.
52. Kasper S, Sheppard PC, Yan Y, et al. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: A model for prostate cancer. Lab Invest 1998;78:i-xv.
53. Shibata MA, Ward JM, Devor DE, Liu ML, Green JE. Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: Histopathological and molecular biological alterations. Cancer Res 1996;56:4894-4903.
54. Tehranian A, Morris DW, Min BH, Bird DJ, Cardiff RD, Barry PA. Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. Am J Pathol 1996;149:1177-1191.
55. Perez-Stable C, Altman NH, Brown J, Harbison M, Cray C, Roos BA. Prostate, adrenocortical, and brown adipose tumors in fetal globin/T antigen transgenic mice. Lab Invest 1996;74:363-373.
56. Garabedian EM, Humphrey PA, Gordon JI. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc Natl Acad Sci USA 1998;95:15382-15387.
57. Skalnik DG, Dorfman DM, Williams DA, Orkin SH. Restriction of neuroblastoma to the prostate gland in transgenic mice. Mol Cell Biol 1991;11:4518-4527.
58. Gabril MY, Onita T, Ji PG, et al. Prostate targeting: PSP94 gene promoter/enhancer region directed prostate tissue-specific expression in a transgenic mouse prostate cancer model. Gene Ther 2002;9:1589-1599.
59. Yan Y, Sheppard PC, Kasper S, et al. Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate 1997;32:129-139.
60. Zhang J, Thomas TZ, Kasper S, Matusik RJ. A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids in vitro and in vivo. Endocrinology 2000;141:4698-4710.
61. Ellwood-Yen K, Graeber TG, Wongvipat J, et al. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 2003;4:223-238.
62. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999;2:70-75.
63. Gingrich JR, Barrios RJ, Morton RA, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996;56:4096-4102.
64. Kaplan-Lefko PJ, Chen TM, Ittmann MM, et al. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55:219-237.
65. Masumori N, Thomas TZ, Chaurand P, et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61:2239-2249.
66. Suttie A, Nyska A, Haseman JK, Moser GJ, Hackett TR, Goldsworthy TL. A grading scheme for the assessment of proliferative lesions of the mouse prostate in the TRAMP model. Toxicol Pathol 2003;31:31-38.
67. Jasani B, Cristaudo A, Emri SA, et al. Association of SV40 with human tumours. Semin Cancer Biol 2001;11:49-61.
68. Barbanti-Brodano G, Sabbioni S, Martini F, Negrini M, Corallini A, Tognon M. Simian virus 40 infection in humans and association with human diseases: Results and hypotheses. Virology 2004;318: 1-9.
69. Pipas JM, Levine AJ. Role of T antigen interactions with p53 in tumorigenesis. Semin Cancer Biol 2001;11:23-30.
70. DeCaprio JA, Ludlow JW, Figge J, et al. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell 1988;54:275-283.
71. Ali SH, DeCaprio JA. Cellular transformation by SV40 large T antigen: Interaction with host proteins. Semin Cancer Biol 2001;11: 15-23.
72. Pallas DC, Shahrik LK, Martin BL, et al. Polyoma small and middle T antigens and SV40 small t antigen form stable complexes with protein phosphatase 2A. Cell 1990;60:167-176.
73. Ewald D, Li M, Efrat S, et al. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science1996;273:1384-1386.
74. Gingrich JR, Barrios RJ, Kattan MW, Nahm HS, Finegold MJ, Greenberg NM. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997;57:4687-4691.
75. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12(Suppl. 2): S145-152.
76. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM. Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Res 2001;61:2736-2743.
77. Huss WJ, Barrios RJ, Foster BA, Greenberg NM. Differential expression of specific FGF ligand and receptor isoforms during angiogenesis associated with prostate cancer progression. Prostate 2003;54:8-16.
78. Huss WJ, Barrios RJ, Greenberg NM. SU5416 selectively impairs angiogenesis to induce prostate cancer-specific apoptosis. Mol Cancer Ther 2003;2:611-616.
79. Foster BA, Gingrich JR, Kwon ED, Madias C, Greenberg NM. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res 1997;57:3325-3330.
80. Masumori N, Tsuchiya K, Tu WH, et al. An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol 2004;171:439-442.
81. Hara M, Kimura H. Two prostate-specific antigens, gammaseminoprotein and beta-microseminoprotein. J Lab Clin Med 1989; 113:541-548.
82. Xuan JW, Kwong J, Chan FL, et al. cDNA, genomic cloning, and gene expression analysis of mouse PSP94 (prostate secretory protein of 94 amino acids). DNA Cell Biol 1999;18:11-26.
83. Ouellette AJ, Selsted ME. Paneth cell defensins: Endogenous peptide components of intestinal host defense. FASEB J1996;10:1280-1289.
84. Perez-Stable C, Altman NH, Mehta PP, Deftos LJ, Roos BA. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res 1997;57:900-906.
85. Kasper S. Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem 2005;94: 279-297.
86. Huss WJ, Maddison LA, Greenberg NM. Autochthonous mouse models for prostate cancer: Past, present and future. Semin Cancer Biol 2001;11:245-260.
87. Abate-Shen C, Shen MM. Mouse models of prostate carcinogenesis. Trends Genet 2002;18:S1-5.
88. Kasper S, Smith JA Jr. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J Urol 2004; 172:12-19.
89. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-531.
90. Zhang X, Lee C, Ng PY, Rubin M, Shabsigh A, Buttyan R. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Prostate 2000;43:278-285.
91. Benson LQ, Coon MR, Krueger LM, Han GC, Sarnaik AA, Wechsler DS. Expression of MXI1, a Myc antagonist, is regulated by Sp1 and AP2. J Biol Chem 1999;274:28794-28802.
92. Schreiber-Agus N, Meng Y, Hoang T, et al. Role of Mxi1 in ageing organ systems and the regulation of normal and neoplastic growth. Nature 1998;393:483-487.
93. Konishi N, Hiasa Y, Tsuzuki T, Tao M, Enomoto T, Miller GJ. Comparison of ras activation in prostate carcinoma in Japanese and American men. Prostate 1997;30:53-57.
94. Scherl A, Li JF, Cardiff RD, Schreiber-Agus N. Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 2004;59:448-459.
95. Voelkel-Johnson C, Voeks DJ, Greenberg NM, et al. Genomic instability-based transgenic models of prostate cancer. Carcinogenesis 2000;21:1623-1627.
96. Zhang X, Chen MW, Ng A, et al. Abnormal prostate development in C3(1)-bcl-2 transgenic mice. Prostate 1997;32:16-26.
97. Bruckheimer EM, Cho S, Brisbay S, et al. The impact of bcl-2 expression and bax deficiency on prostate homeostasis in vivo. Oncogene 2000;19:2404-2412.
98. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000;100:387-390.
99. Di Cristofano A, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat Genet 1998;19:348-355.
100. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/ Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-1568.
101. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-1 178.
102. Wang S, Gao J, Lei Q, et al. Prostate-specifi c deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003;4:209-221.
103. Vazquez F, Sellers WR. The PTEN tumor suppressor protein: An antagonist of phosphoinositide 3-kinase signaling. Biochim Biophys Acta Rev Cancer 2000;1470:M21-M35.
104. Sun M, Wang G, Paciga JE, et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001;159:431-437.
105. Majumder PK, Yeh JJ, George DJ, et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: The MPAKT model. Proc Natl Acad Sci USA 2003;100:7841-7846.
106. Bhatia-Gaur R, Donjacour AA, Sciavolino PJ, et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev 1999;13: 966-977.
107. Voeller HJ, Augustus M, Madike V, Bova GS, Carter KC, Gelmann EP. Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res 1997;57:4455-4459.
108. He WW, Sciavolino PJ, Wing J, et al. A novel human prostatespecifi c, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 1997;43:69-77.
109. Chang M, Tsuchiya K, Batchelor RH, et al. Deletion mapping of chromosome 8p in colorectal carcinoma and dysplasia arising in ulcerative colitis, prostatic carcinoma, and malignant fibrous histiocytomas. Am J Pathol 1994;144:1-6.
110. Matsuyama H, Pan Y, Skoog L, et al. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization. Oncogene 1994;9:3071-3076.
111. Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002;22:1495-1503.
112. Berges RR, Vukanovic J, Epstein JI, et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995;1:473-480.
113. Cordon-Cardo C, Koff A, Drobnjak M, et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-1291.
114. Shim EH, Johnson L, Noh HL, et al. Expression of the F-box protein SKP2 induces hyperplasia, dysplasia, and low-grade carcinoma in the mouse prostate. Cancer Res 2003;63:1583-1588.
115. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-221.
116. Wang Y, Hayward SW, Donjacour AA, et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000;60: 6008-6017.
117. Foster BA, Evangelou A, Gingrich JR, Kaplan PJ, DeMayo F, Greenberg NM. Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. Differentiation 2002;70:624-632.
118. Song Z, Wu X, Powell WC, et al. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: A new mouse model for prostatic intraepithelial neoplasia. Cancer Res 2002;62:5096-5105.
119. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
120. DiGiovanni J, Kiguchi K, Frijhoff A, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000;97:3455-3460.
121. Konno-Takahashi N, Takeuchi T, Shimizu T, et al. Engineered IGF-I expression induces glandular enlargement in the murine prostate. J Endocrinol 2003;177:389-398.
122. Derynck R. TGF-beta-receptor-mediated signaling. Trends Biochem Sci 1994;19:548-553.
123. Wikstrom P, Lindh G, Bergh A, Damber JE. Alterations of transforming growth factor beta1 (TGF-beta1) and TGFbeta receptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines. Urol Res 1999;27:185-193.
124. Serra R, Johnson M, Filvaroff EH, et al. Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol 1997;139:541-552.
125. Tu WH, Thomas TZ, Masumori N, et al. The loss of TGF-beta signaling promotes prostate cancer metastasis. Neoplasia 2003;5:267-277.
126. Di Lorenzo G, Autorino R, De Laurentiis M, et al. HER-2/neu receptor in prostate cancer development and progression to androgen independence. Tumori 2004;90:163-170.
127. Li Z, Szabolcs M, Terwilliger JD, Efstratiadis A. Prostatic intraepithelial neoplasia and adenocarcinoma in mice expressing a probasin-Neu oncogenic transgene. Carcinogenesis 2006;27:1054-1067.
128. Feldman BJ, Feldman D. The development of androgenindependent prostate cancer. Nat Rev Cancer 2001;1:34-45.
129. Stanbrough M, Leav I, Kwan PW, Bubley GJ, Balk SP. Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci USA 2001;98: 10823-10828.
130. Fong CJ, Sutkowski DM, Braun EJ, et al. Effect of retinoic acid on the proliferation and secretory activity of androgen-responsive prostatic carcinoma cells. J Urol 1993;149:1190-1194.
131. Skowronski RJ, Peehl DM, Feldman D. Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993;132:1952-1960.
132. Allegretto E, McClurg M, Lazarchik S, et al. Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism. J Biol Chem 1993;268:26625-26633
133. [published erratum appears in J Biol Chem 1994;269(10):7834].
134. Huang J, Powell WC, Khodavirdi AC, et al. Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res 2002;62: 4812-4819.
135. Bruckheimer EM, Brisbay S, Johnson DJ, Gingrich JR, Greenberg N, McDonnell TJ. Bcl-2 accelerates multistep prostate carcinogenesis in vivo. Oncogene 2000;19:5251-5258.
136. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-224.
137. Kim MJ, Cardiff RD, Desai N, et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc Natl Acad Sci USA 2002;99:2884-2889.
138. Abate-Shen C, Banach-Petrosky WA, Sun X, et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 2003;63:3886-3890.
139. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsuffi ciency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-11568.
140. Polnaszek N, Kwabi-Addo B, Peterson LE, et al. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer. Cancer Res 2003;63:5754-5760.
141. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001;61: 5692-5696.
142. Stamey TA, Warrington JA, Caldwell MC, et al. Molecular genetic profi ling of Gleason grade 4/5 prostate cancers compared to benign prostatic hyperplasia. J Urol 2001;166:2171-2177.
143. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifi es candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-5978.
144. Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ, Vasioukhin V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004;6:185-195.
145. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fi broblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848-851.
146. Watabe T, Lin M, Ide H, et al. Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter. Proc Natl Acad Sci USA 2002;99:401-406.
147. Nature Cell Migration Consortium (CMC). http://www.cellmigration. org/resource/komouse/komouse-approaches.shtml.
148. Duan W, Gabril MY, Moussa M, et al. Knockin of SV40 Tag oncogene in a mouse adenocarcinoma of the prostate model demonstrates advantageous features over the transgenic model. Oncogene 2005;24:1510-1524.